159 related articles for article (PubMed ID: 22786815)
1. Identifying combined design and analysis procedures in two-stage trials with a binary end point.
Bowden J; Wason J
Stat Med; 2012 Dec; 31(29):3874-84. PubMed ID: 22786815
[TBL] [Abstract][Full Text] [Related]
2. Conditional estimation using prior information in 2-stage group sequential designs assuming asymptotic normality when the trial terminated early.
Shimura M; Maruo K; Gosho M
Pharm Stat; 2018 Sep; 17(5):400-413. PubMed ID: 29687592
[TBL] [Abstract][Full Text] [Related]
3. Interval and point estimation in adaptive Phase II trials with binary endpoint.
Nhacolo A; Brannath W
Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
[TBL] [Abstract][Full Text] [Related]
4. An MSE-reduced estimator for the response proportion in a two-stage clinical trial.
Li Q
Pharm Stat; 2011; 10(3):277-9. PubMed ID: 20140880
[TBL] [Abstract][Full Text] [Related]
5. Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection.
Carreras M; Brannath W
Stat Med; 2013 May; 32(10):1677-90. PubMed ID: 22744936
[TBL] [Abstract][Full Text] [Related]
6. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
Li W; Chen C; Li X; Beckman RA
Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
[TBL] [Abstract][Full Text] [Related]
7. Point estimation following a two-stage group sequential trial.
Grayling MJ; Wason JM
Stat Methods Med Res; 2023 Feb; 32(2):287-304. PubMed ID: 36384365
[TBL] [Abstract][Full Text] [Related]
8. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
Trials; 2011 Mar; 12():81. PubMed ID: 21418571
[TBL] [Abstract][Full Text] [Related]
9. Interim analysis of binary outcome data in clinical trials: a comparison of five estimators.
Lu QS; Chow SC; Tse SK
J Biopharm Stat; 2019; 29(2):400-410. PubMed ID: 30599798
[TBL] [Abstract][Full Text] [Related]
10. On sample size determination in multi-armed confirmatory adaptive designs.
Wassmer G
J Biopharm Stat; 2011 Jul; 21(4):802-17. PubMed ID: 21516570
[TBL] [Abstract][Full Text] [Related]
11. What inference for two-stage phase II trials?
Porcher R; Desseaux K
BMC Med Res Methodol; 2012 Aug; 12():117. PubMed ID: 22867439
[TBL] [Abstract][Full Text] [Related]
12. Point and interval estimation of primary and secondary parameters in a two-stage adaptive clinical trial.
Liu A; Wu C; Yu KF
J Biopharm Stat; 2008; 18(2):211-26. PubMed ID: 18327717
[TBL] [Abstract][Full Text] [Related]
13. Precision of maximum likelihood estimation in adaptive designs.
Graf AC; Gutjahr G; Brannath W
Stat Med; 2016 Mar; 35(6):922-41. PubMed ID: 26459506
[TBL] [Abstract][Full Text] [Related]
14. Impact of lack-of-benefit stopping rules on treatment effect estimates of two-arm multi-stage (TAMS) trials with time to event outcome.
Choodari-Oskooei B; Parmar MK; Royston P; Bowden J
Trials; 2013 Jan; 14():23. PubMed ID: 23343147
[TBL] [Abstract][Full Text] [Related]
15. Choice of futility boundaries for group sequential designs with two endpoints.
Schüler S; Kieser M; Rauch G
BMC Med Res Methodol; 2017 Aug; 17(1):119. PubMed ID: 28789615
[TBL] [Abstract][Full Text] [Related]
16. Interim analysis incorporating short- and long-term binary endpoints.
Niewczas J; Kunz CU; König F
Biom J; 2019 May; 61(3):665-687. PubMed ID: 30694566
[TBL] [Abstract][Full Text] [Related]
17. Point estimation following two-stage adaptive threshold enrichment clinical trials.
Kimani PK; Todd S; Renfro LA; Stallard N
Stat Med; 2018 Sep; 37(22):3179-3196. PubMed ID: 29855066
[TBL] [Abstract][Full Text] [Related]
18. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.
Hamasaki T; Evans SR; Asakura K
J Biopharm Stat; 2018; 28(1):28-51. PubMed ID: 29083951
[TBL] [Abstract][Full Text] [Related]
19. Point estimation in adaptive enrichment designs.
Kunzmann K; Benner L; Kieser M
Stat Med; 2017 Nov; 36(25):3935-3947. PubMed ID: 28783881
[TBL] [Abstract][Full Text] [Related]
20. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
